Anti-CD28 compositions

Provided herein are novel anti-CD28×anti-B7H3 (also referred to as "αCD28×αB7H3") heterodimeric bispecific antibodies and methods of using such antibodies for the treatment of cancers. Subject αCD28×αB7H3 antibodies are capable of agonistically binding to CD28 costimulatory molecules on T...

Full description

Saved in:
Bibliographic Details
Main Authors Hedvat, Michael, Gusti Zeng, Veronica, Moore, Gregory, Diaz, Juan, Desjarlais, John R
Format Patent
LanguageEnglish
Published 05.03.2024
Subjects
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online AccessGet full text

Cover

More Information
Summary:Provided herein are novel anti-CD28×anti-B7H3 (also referred to as "αCD28×αB7H3") heterodimeric bispecific antibodies and methods of using such antibodies for the treatment of cancers. Subject αCD28×αB7H3 antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and targeting to B7H3 on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful for enhancing anti-tumor activity when used in combination with other anti-cancer therapies.
Bibliography:Application Number: US202117407135